. 2017 Aug 22;8(44):76479–76491. doi: 10.18632/oncotarget.20385

Table 2. Mutational profile of the panel of breast cancer cell lines and IC₅₀ doses for cell growth inhibition of single treatment with anti-microtubules chemotherapy, taselisib and ipatasertib.

Cell line	PI3KCA status	IC50 Vinorelbine	IC50 Paclitaxel	IC50 Eribulin	IC50 Taselisib	IC50 Ipatasertib
BT474	p.K111N mutation	80 nM	10 nM	1 nM	10 nM	0,5 μM
KPL-4	p.H1047L mutation	150 nM	1 nM	2.5 nM	50 nM	0,5 μM
SUM159	p.H1047L mutation	150 nM	50 nM	5 nM	50 nM	2 μM
MCF-7	p.E545K mutation	100 nM	20 nM	2 nM	100 nM	1,5 μM
MDA-MB231	Wild-type	100 nM	2.5 nM	1 nM	500 nM	10 μM
MDA-MB468	Wild-type	100 nM	2.5 nM	1.5 nM	500 nM	10 μM

1. American Type Culture Collection (ATCC, Manassas, VA, USA).

Table 2. Mutational profile of the panel of breast cancer cell lines and IC50 doses for cell growth inhibition of single treatment with anti-microtubules chemotherapy, taselisib and ipatasertib.